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Abstract
Background: In 2005, Rwanda drafted a national TB/HIV policy and began scaling-up collaborative TB/HIV activities.
Prior to the scale-up, we evaluated existing TB/HIV practices, possible barriers to policy and programmatic
implementation, and patient treatment outcomes. We then used our evaluation data as a baseline for evaluating
the national scale-up of collaborative TB/HIV activities from 2005 through 2009.
Methods: Our baseline evaluation included a cross-sectional evaluation of 23/161 TB clinics. We conducted
structured interviews with patients and clinic staff and reviewed TB registers and patient records to assess HIV
testing practices, provision of HIV care and treatment for people with TB that tested positive for HIV, and patients’
TB treatment outcomes. Following our baseline evaluation, we used nationally representative TB/HIV surveillance
data to monitor the scale-up of collaborative TB/HIV activities
Results: Of 207 patients interviewed, 76% were offered HIV testing, 99% accepted, and 49% reported positive test
results. Of 40 staff interviewed, 68% reported offering HIV testing to >50% of patients. From 2005-2009, scaled-up
TB/HIV activities resulted in increased HIV testing of patients with TB (69% to 97%) and provision of cotrimoxazole
(15% to 92%) and antiretroviral therapy (13% to 49%) for patients with TB disease and HIV infection (TB/HIV). The
risk of death among patients with TB/HIV relative to patients with TB not infected with HIV declined from 2005 (RR
= 6.1, 95%CI 2.6, 14.0) to 2007 (RR = 1.8, 95%CI 1.68, 1.94).
Conclusions: Our baseline evaluation highlighted that staff and patients were receptive to HIV testing. However,
expanded access to testing, care, and treatment was needed based on the proportion of patients with TB having
unknown HIV status and the high rate of HIV infection and poorer TB treatment outcomes for patients with TB/HIV.
Following our evaluation, scale-up of TB/HIV services resulted in almost all patients with TB knowing their HIV
status. Scale-up also resulted in dramatic increases in the uptake of lifesaving HIV care and treatment coinciding
with a decline in the risk of death among patients with TB/HIV.
Background
Tuberculosis (TB) is a treatable disease but remains the
leading cause of death among persons living with HIV/
AIDS (PLHIV) [1]. In some settings, up to 50% of
patients with both TB disease and HIV infection die dur-
ing TB treatment with most deaths occurring within 2
months of being diagnosed with TB [2-6]. In 2004, the
World Health Organization (WHO) issued policy gui-
dance on collaborative TB/HIV activities to reduce the
burden of TB and HIV [7]. The interim policy recom-
mended routine HIV testing for patients with TB disease
and ensuring linkages to HIV care and treatment for
patients with TB disease diagnosed with HIV infection
(hereafter patients with both TB disease and HIV infec-
tion will be referred to as patients with TB/HIV). Also in
2004, WHO and UNAIDS issued a joint policy statement
recommending routine provider-initiated HIV testing
and counseling (PITC) for all patients with TB [8]. The
policy recommendations were intended to increase the
uptake of HIV testing among patients with TB by shifting
from a model of people voluntarily seeking HIV counsel-
ing and testing (VCT) to providers initiating HIV testing
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resulted in TB clinics serving as points of entry for scale-
up of HIV care and treatment services.
In 2005, Rwanda was experiencing a generalized HIV
epidemic with 3% of the adult population living with HIV
[9]. WHO estimated that the incidence of TB disease in
Rwanda was 361 per 100,000 population and 41% of
patients with TB disease were infected with HIV [10].
There were 161 TB clinics in Rwanda and all were using
WHO’s Directly Observed Treatment Short-Course
(DOTS) strategy for the management of TB disease. New
cases of pulmonary TB were treated with a standardized
regimen of fixed-dose combinations of rifampicin, isonia-
zid, ethambutol, and pyrazinimide taken daily for two
months (intensive phase) and then a fixed-dose combina-
tion tablet of rifampicin and isoniazid administered three
days a week for four months (continuation phase). In
2005, patients with TB/HIV were eligible for antiretroviral
therapy (ART) if they had a CD4
+ cell count < 350 cells/
mm
3 [11]. For the majority of patients with TB/HIV, ART
included efavirenz-based regimens initiated after complet-
ing the two month intensive phase of anti-TB treatment.
In response to the TB/HIV syndemic [12-14] and the
new TB/HIV guidance from WHO, Rwanda’sn a t i o n a l
TB program (NTP) drafted and approved a national pol-
icy on collaborative TB/HIV activities in December of
2005. The new national TB/HIV policy included provi-
der-initiated HIV testing and counseling for all patients
with TB as well as the provision of HIV care and treat-
ment for patients with TB/HIV. Prior to implementing
the policy and in the absence of nationally representa-
tive TB/HIV surveillance data, the NTP wanted to col-
lect baseline data and identify possible barriers to
routine HIV testing for patients with TB.
In October 2005, we evaluated current TB/HIV prac-
tices in health facilities providing TB services and identi-
fied possible barriers to implementing the new TB/HIV
policy. The objectives of our evaluation were to 1) collect
data to inform the national scale-up of HIV services in
TB facilities, and to 2) provide baseline data by which to
evaluate the scale-up of activities using national surveil-
lance data. To inform the scale-up of activities we
focused on assessing staff awareness of the relationship
between TB and HIV, activities in support of TB/HIV
coordination, determining what proportion of patients
with TB were being offered HIV testing, evaluating the
acceptability of HIV testing among patients with TB, and
documenting whether or not patients with TB/HIV were
receiving cotrimoxazole prophylaxis (CTX) and ART.
Methods
Baseline Evaluation
We conducted the evaluation in a non-probability sam-
p l eo f2 3o f1 6 1( 1 4 % )T Bc l i n i c si nR w a n d a .T h e
sample of TB clinics was selected by the NTP to repre-
sent all provinces of the country and include a mix of
urban and rural health centers and hospitals providing
TB diagnostic and treatment services.
The three evaluation components were 1) structured
interviews with patients arriving at the clinics to receive
their anti-TB medications, 2) structured interviews with
s t a f fw o r k i n ga tt h eT Bc l i n i c s ,a n d3 )r e v i e wo ft h eT Br e g -
isters and patient treatment cards for patients registered for
anti-TB treatment during a specified three month period.
All data collection forms were piloted and revised based on
focus group discussions with patients receiving anti-TB
treatment and staff working at the TB clinics of two sites
not selected to participate in the evaluation. Data collectors
fluent in Kinyarwanda, French, and English were trained to
lead the focus group discussions. Data collection forms,
focus group guides, and resultant transcripts were trans-
lated from English to Kinyarwanda and then back trans-
lated to ensure proper translation.
From October 1 to October 14, 2005, we collected
baseline data using two teams consisting of staff from
the NTP, CDC, and medical students from the National
University of Rwanda. All data collectors participated in
a two-day skills-based training on leading focus groups,
conducting structured interviews, using the data collec-
tion tools, data entry, and ensuring the protection of
study participants.
Structured interviews with patients
We approached the first 10 patients arriving for anti-TB
treatment at each clinic. After receiving oral informed
consent, we conducted structured interviews including
both open and closed-ended questions. We interviewed
patients to assess their experiences with HIV testing
with a focus on what encouraged them or prevented
them from getting HIV testing. For patients who dis-
closed being infected with HIV, we asked whether or
not they were receiving CTX and ART. For patients not
tested, we asked if they would accept HIV testing if
offered and, if not, why?
Structured interviews with staff
We interviewed 1-2 staff at each clinic, depending on
the number of staff working at the clinic and their work
burden at the time of our visit. We asked staff open and
closed-ended questions to assess their awareness of the
association between TB and HIV, their knowledge of
risk factors associated with TB disease, and the percen-
tage of patients with TB offered HIV testing and coun-
seling. We also asked them to describe any perceived
barriers to offering HIV testing to patients with TB.
Lastly, we asked about services routinely provided for
patients with TB/HIV.
Review of TB registers and patient treatment cards
We reviewed the TB registers and patient treatment
cards for all patients registered for anti-TB treatment
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fourth quarter of 2004, because we wanted to evaluate
how HIV impacted the risk of death among people
with TB and at the time of our evaluation these
patients were the most recent quarterly cohort with
documented treatment outcomes. Registers were
reviewed to determine the proportion of patients with
documented HIV test results prior to transitioning
from VCT to PITC and to compare TB treatment out-
comes for patients based on their HIV status. We
abstracted data on patient demographics, TB diagnosis
(pulmonary versus extrapulmonary), treatment cate-
gory (new versus re-treatment), treatment outcome
(cured, completed, died, defaulted, or transferred out),
HIV status, and receipt of CTX and/or initiation of
ART for patients with TB/HIV.
Evaluating the Scale-up of Collaborative TB/HIV Activities
We measured the scale-up of collaborative TB/HIV
activities by comparing our baseline evaluation data to
select TB/HIV indicators routinely collected by all TB
clinics in Rwanda and reported to the national TB pro-
gram. District level reports are compiled and trans-
mitted to the NTP following quarterly district-level
evaluation meetings. All districts report to the NTP and
the quality and completeness of the TB/HIV data are
routinely evaluated during supportive supervision visits.
Using the nationally representative data provided by the
Ministry of Health, we compared the proportion of
patients with TB getting an HIV test, testing positive,
and among those testing positive the proportion getting
CTX and ART from 2005 to 2009. Our crude analysis
of the risk of death among patients with TB/HIV rela-
tive to patients with TB not infected with HIV was lim-
ited to the years for which patients’ anti-TB treatment
outcomes could be linked to their HIV testing data (i.e.,
our baseline data and enhanced surveillance done in
2007).
Statistical analysis
We calculated descriptive statistics for data from each of
the three components of the evaluation. We performed
Pearson’s Χ
2 test to examine the association between
dying during anti-TB treatment and patients’ HIV sta-
tus. For our crude analysis of the risk of death during
anti-TB treatment, we excluded patients who defaulted
or transferred out because we could not determine
whether they survived or died.
Ethical approval
The evaluation protocol underwent ethical review and
was determined to be a program evaluation and not
research by CDC, the Rwandan Ministry of Health, and
Columbia University.
Results
Baseline Evaluation
All geographic regions of the country were represented
by the sample of 23 TB clinics and the geographic dis-
tribution of the sample approximated the distribution of
clinics nationally (Table 1). Our sample underrepre-
sented health centers (48% of our sample relative to
70% nationally) and overrepresented district hospitals
(44% of our sample relative to 20% nationally). On-site
HIV testing and ART services were available at 74% and
65% of the health facilities in our sample compared to
70% and 41% of facilities nationally.
Structured interviews with patients
Of the 207 patients with TB we interviewed, 81 (39%)
were female, median age was 37 years, 113 (55%) had
completed primary school and 63 (30%) had no formal
education. We interviewed an average of nine patients
per site depending on the number of patients presenting
at the clinics for treatment at the time of our site visits
(range 1 to 14 patients interviewed per site). Patient
consent to participate was nearly 100% with refusals
being so rare that data collectors stopped routinely doc-
umenting them.
Of the 207 patients interviewed, 158 (76%) reported
being offered an HIV test at the time of TB diagnosis.
Of those, 157 (99%) accepted testing and received their
results (Figure 1). Among 134 (85%) patients who dis-
closed their test results to interviewers, 66 (49%)
reported a positive HIV test result. Among the 49
patients not offered a test, 9 had been previously tested
and 32 of the 40 not previously tested (80%) responded
Table 1 Characteristics of evaluation sites and all TB
facilities in Rwanda, 2005
Evaluation Sites (n =
23)
All TB Facilities (N =
161)
No. % No. %
Province
Kigali City 4 18 22 14
Northern 5 22 22 14
Southern 6 26 42 26
Eastern 4 17 35 22
Western 4 17 40 24
Facility type
Health center 11 48 113 70
District hospital 10 44 33 20
Referral hospital 2 8 4 3
Other 0 0 11 7
On-site HIV services
VCT* 17 74 113 70
ART
† 15 65 66 41
* VCT = Voluntary HIV Counseling and Testing
†ARV = antiretroviral therapy
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them by staff at the TB clinic. Overall, 81% (167/207) of
patients knew their status either because they were
offered and accepted testing or they had been previously
tested.
Patients who reported accepting HIV testing in TB
services (n = 157) were asked what convinced them to
get tested. Patients could provide multiple responses
with the most common reasons cited for getting an HIV
test being the patient’s desire to know their HIV status
(71%, n = 110), recommendation by a health care
w o r k e r( 3 5 % ,n=5 5 ) ,a n dp o s s i b l ee x p o s u r et oH I V
through unprotected sexual intercourse (25%, n = 38).
Among the seven patients not offered a test, not pre-
v i o u s l yt e s t e d ,a n dw h ow o u l dr e f u s eat e s ti fo f f e r e d ;
the most common reasons cited for not getting tested
were that they did not perceive themselves to be at risk
for HIV infection (n = 4) or feared a positive test result
(n = 2).
Patients with TB/HIV were asked whether someone
talked with them about starting CTX and/or ART and
whether they had initiated ART. For the 66 patients
who disclosed a positive HIV test result, 97% (64/66)
recalled talking with someone about taking CTX to pre-
vent opportunistic infections, 89% (59/66) reported
meeting with someone to discuss ART, and 53% (35/66)
responded that they were currently receiving ART.
Structured interviews with staff
We interviewed 40 staff from the 23 TB clinics, includ-
ing 35 (88%) nurses, one nurse assistant, one medical
assistant, one TB/HIV focal person, and one health cen-
ter director. Staff awareness of the relationship between
TB and HIV was evaluated by asking open-ended ques-
tions about risk factors for developing TB disease and
the leading cause of death among PLHIV. Among the
40 staff, 35% (14/40) correctly identified TB disease as
the leading cause of death among PLHIV. When asked
to identify the most common risk factors for PLHIV
developing TB disease, staff mentioned HIV infection or
immune suppression (83%), contact with another person
with TB disease (75%), malnutrition (58%), and poverty
(13%).
When asked about the percentage of patients with TB
offered HIV testing at their TB clinics, 11 (32%) staff
reported their clinic offered testing to all patients, 16
(47%) reported their clinic offered to more than half of
patients, seven (21%) to less than half of patients, and
six did not know. We then asked staff to talk about bar-
riers to offering HIV testing to patients with TB. The
most frequently mentioned barriers as perceived by staff
were lack of trained staff (43%), insufficient space for
testing and counseling (33%), and patient concerns
about stigmatization associated with HIV testing (25%)
(Table 2).
Figure 1 HIV Testing Among Patients with TB.
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for patients with TB after HIV testing and counseling.
For patients with a positive HIV test result, 90% (36/40)
of staff reported that patients at their facility receive
counseling, 65% (26/40) receive ART, 65% (26/40) CTX,
65% condoms, and 10% (4/40) nutritional support. For
patients with a negative HIV test result, 93% (37/40) of
staff reported providing counseling on risk reduction,
58% (23/40) assessed patient’s risk of HIV infection,
35% (14/40) offered condoms only to patients believed
to be at high risk for HIV infection and 10% (4/40)
offered condoms to all patients.
Review of TB registers and patient treatment cards
During the fourth quarter of 2004 (the most recent
cohort with treatment outcomes at the time of our base-
line evaluation) there were 542 patients registered for
anti-TB treatment at the 23 TB clinics; 211 (39%) were
female and the mean age of patients was 32.8 years (SD
14.1) (Table 3). Overall, 77% (n = 416) of patients were
diagnosed with pulmonary disease and 80% (435/542)
were new patients with no known history of being
previously treated for TB disease. HIV test results were
documented in the TB register for 48% of patients (n =
258), in the patient treatment cards for 38% (n = 208),
and either the TB register or patient treatment cards for
52% (n = 282) of patients. Among patients with a docu-
mented HIV test, 44% (122/277) had a positive test
result. Of the 122 patients with a positive HIV test
result, there was documentation in the register or their
patient treatment cards that 2.5% (3/122) were receiving
CTX and 12.3% (15/122) had initiated ART.
Among patients with documented anti-TB treatment
outcomes, 69% (n = 336) had successful outcomes (i.e.,
either cured or completed) and 11.1% (n = 60) died
before completing anti-TB treatment. Treatment out-
comes differed based on patients’ HIV status (Table 4).
The crude risk of death among patients with TB/HIV
was 6.1 (95% CI 2.6, 14.0) times the risk among patients
with TB not infected with HIV. The crude risk of death
among patients with TB and undocumented HIV status
was 2.9 (95% CI 1.2, 6.9) times the risk among patients
with TB not infected with HIV.
Evaluation of the Scale-up of Collaborative TB/HIV
Activities
The proportion of patients with TB having HIV test
results documented in the TB register increased from
48% during our baseline evaluation to 69% during the
first year of scale-up in 2005, and then increased to 97%
in 2009 (Figure 2). Provision of CTX for people with
TB/HIV increased from the 2.5% noted during our eva-
luation to 15% in 2005 and then to 92% in 2009 [12,13].
The proportion of people with TB/HIV initiating ART
increased from the 12.5% at baseline to 13% in 2005
and 49% in 2009 [15,16]. The most recent year with
reported data on anti-TB treatment outcomes stratified
by HIV status was 2007 and the risk of death during
anti-TB treatment among patients with TB/HIV was 1.8
times greater (95% CI 1.68, 1.94) than the risk among
patients with TB not infected with HIV [16]. The rela-
tive risk of death in 2007 (RR = 1.8, 95% CI 1.68, 1.94)
was less than the relative risk calculated for patients in
Table 2 Barriers to offering HIV testing reported by TB
clinic staff
n* (%)
Not enough trained staff 17 (43)
Not enough space 13 (33)
Patient’s concern about stigma of test 10 (25)
Responsibility of VCT clinic 6 (15)
Not enough supplies 5 (13)
Staff uncomfortable offering the test 4 (10)
* Staff could give multiple responses
Table 3 Patient and disease characteristics and TB
treatment outcomes (N = 542 patients registered during
the 4
th Quarter of 2004)
Characteristic No. (%)
Female 211 (38.9)
Mean age in years 32.8 SD*14.2
Pulmonary TB 416 (76.8)
New patient 435 (80.3)
HIV Status
Positive 122 (22.5)
Negative 155 (28.6)
Not documented 265 (48.9)
Treatment outcomes
†
Cured 198 (36.5)
Completed 138 (25.5)
Died 60 (11.1)
Defaulted 15 (2.8)
Transferred out 76 (14.0)
*SD = standard deviation
† Missing outcomes for 10.1% (n = 55) of patients registered
Table 4 TB treatment outcomes* by HIV status for
patients registered during the 4
th quarter of 2004
(n = 358)
Treatment
success
Died Risk of death
n (%) N (%) RR 95% CI
HIV positive (n = 90) 63 (70) 27 (30) 6.1 (2.6 -14.0)
HIV negative (n = 121) 115 (95) 6 (5) Referent Referent
HIV unknown (n = 147) 126 (86) 21 (14) 2.9 (1.2-6.9)
* Analysis limited to patients with anti-TB treatment outcomes of success
(cured and completed) or death
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that did not overlap (RR = 6.1, 95% CI 2.6, 14.0).
Discussion
We conducted this evaluation to collect baseline data to
support and inform the implementation and ongoing
scale-up of the new national TB/HIV policy in Rwanda.
Multiple data sources were used in order to compare
and contrast what patients reported, what staff reported,
and what was documented about HIV testing for
patients with TB and care and treatment for patients
with TB/HIV. Our interpretations of the evaluation data
were that patients with TB and staff at TB clinics were
receptive to HIV testing which supports the premise
that TB clinics could be an important point of entry
into life-saving HIV care and treatment services in
Rwanda. Review of subsequent programmatic data con-
firms the success of the national scale-up of key TB/
H I Vs e r v i c e sa n ds u g g e s t sas u b s t a n t i a lp u b l i ch e a l t h
impact from these efforts.
From patient interviews we learned that when offered,
almost all patients (99%) reported accepting HIV testing.
The almost universal acceptance of HIV testing by
patients and the stated willingness to accept testing by
p a t i e n t sn o to f f e r e dH I Vt e s t i n g ,s u g g e s t e dt h a ti m p l e -
menting routine PITC for all patients with TB disease
could dramatically increase testing uptake. However,
interviews with TB clinic staff revealed that less than a
third of staff reported offering HIV testing to all patients
with TB and only 38% knew that TB was the leading
cause of death among PLHIV. Additionally, our review
of patient records revealed that there was no documen-
tation of HIV test results for almost half (48%) of
patients registered for TB treatment. The lack of
documentation indicated that staff were either not routi-
nely offering or documenting HIV testing. Inconsistent
documentation of HIV information could result in
missed opportunities for eligible patients to initiate ART
and underestimation of the burden of disease and
resources needed to treat TB/HIV. Similarly, based on
available data it was not possible to determine how
much of the change in the proportion of patients receiv-
ing CTX or ART is due to enhanced services versus
improved data recording and reporting. These discre-
pancies identified during our evaluation highlight the
importance of routinely evaluating surveillance systems
to ensure completeness and accuracy of surveillance
data. To support the scale-up of TB/HIV activities,
resources were needed to train staff about the relation-
ship between TB/HIV and the importance of routinely
offering HIV testing and documenting patients’ test
results.
The proportion of patients with TB disease and HIV
infection based on patient interviews (49%) and clinical
record reviews (42%) were consistent with the national
data (46%) in 2005. Patients with TB and HIV infection
were more likely to die during anti-TB treatment than
patients with TB not infected with HIV. Also, our find-
ing that patients with unknown HIV status had a greater
risk of death than patients with HIV negative test results
suggests that the group with unknown HIV serostatus
probably contained people with undiagnosed HIV. Our
finding of an increased risk of death during anti-TB
treatment for people infected with HIV is consistent
with other published reports [17,18] and highlights the
importance of routine HIV testing to minimize delays in
HIV diagnosis and initiation of ART to reduce the risk
of death among patients with TB/HIV [19-21].
Figure 2 Trends in HIV testing, HIV infection, and HIV care and treatment for patients with TB in Rwanda, baseline evaluation data
from 2005 and nationally reported data from 2005 - 2009.
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were urgently needed based on the proportion of
patients with unknown HIV status, the high rate of HIV
infection coupled with poorer TB treatment outcomes,
and the lack of documented CTX and ART for patients
with TB/HIV.
In response to the evaluation findings, the MOH mod-
ified their draft TB/HIV policy in November 2005, to
specify that CTX should be routinely provided through
the TB program for all patients with TB/HIV. Evalua-
tion findings were used to plan and implement national,
regional, and district trainings on PITC and to ensure
that patients with TB/HIV receive CTX and ART when
indicated. The National TB and HIV Programs led the
implementation of TB/HIV collaborative activities, start-
ing with revision of program guidelines, training materi-
als, and monitoring and evaluation tools. TB/HIV
collaborative activities were implemented and refined at
two model centers prior to national scale-up. An assess-
ment was conducted to identify the training needs of
health service staff to inform the development and
decentralized implementation of an integrated TB/HIV
curriculum. The curriculum emphasized cross-training
and was implemented with staff at district-level health
facilities providing quality assured TB diagnostic and
treatment services and ART. The two model centers
were used as practical training centers and implementa-
tion fidelity was assured through intensive site support
visits that included clinical mentorship and ongoing
monitoring and evaluation of key indicators.
Rwanda has achieved dramatic increases in HIV testing
and provision of CTX and ART for patients with TB/HIV
[22-24]. The risk of death among patients with TB/HIV
has decreased as HIV testing and the provision of CTX
and ART has been scaled-up. The noted decrease in the
relative risk of death among patients with TB/HIV (from
6.1 to 1.8 with non-overlapping confidence intervals) is
encouraging but should be interpreted with caution
because the comparison is based on cross-sectional data.
In 2006, in response to increasing evidence that early
initiation of ART substantially improves the survival of
patients with TB/HIV [25], Rwanda began implementing a
“one-stop” TB-HIV integrated services model where ART
is provided to patients with TB/HIV at TB Diagnostic and
Treatment Centers (DTC). By April 2009, the “one-stop”
TB-HIV integration model had already been adopted by
80% (153 of 192) of TB clinics (personal communication
with Director of the NTP), which should further expand
ART coverage for people with TB/HIV. The NTP aims to
reach 100% coverage of CTX as it is a relatively inexpen-
sive, safe, and life-saving intervention [26]. Evaluation
research is now needed to document the operationaliza-
tion and impact of the “one-stop” approach, especially in
light of the WHO’s “3I ’s” initiative (intensified TB case-
finding, isoniazid preventive therapy, and infection con-
trol), which calls for greater integration and provision of
services for people with TB/HIV [27].
Our evaluation findings were based on a non-probabil-
ity sample of TB clinics, staff, and patients, and therefore
may not have been representative of all TB clinics in the
country. Despite the higher proportions of district and
referral hospital-based clinics in our non-probability
sample compared with national TB clinics, we do not
believe that the former was biased towards selecting
“top-performing sites,” as the performance indicators (e.
g., HIV testing, provision of CTX/ART) from our sample
were lower than national estimates from 2005. Data from
patients and health care workers were based on self-
report and therefore are subject to recall and social desir-
ability bias. Data from healthcare workers or TB registers
on the provision of ART underestimate the uptake of
ART because the denominator includes an undetermin-
able number of patients with TB who were not eligible
for ART based on their CD4 cell counts (note: the CD4
threshold below which people are eligible for ARVs
increased from 200 to 350 in 2008). We were unable to
ascertain the true outcome status of patients receiving
anti-TB treatment who had defaulted, which may have
resulted in an underestimation of mortality. Despite the
aforementioned limitations, our baseline estimates of
HIV infection among patients with TB and provision of
CTX and ART for patients with TB/HIV were consistent
with 2005 national estimates that were released after our
evaluation. We were not able to perform survival analyses
and our estimates of the risk of death during TB treat-
ment are unadjusted because patient-level data for possi-
ble confounders were not available.
Conclusions
Using three sources of data, we were able to demon-
strate that patients and staff were receptive to HIV test-
ing and that TB clinics could serve as a point of entry
into HIV care and treatment. Patients’ acceptance of
and staff willingness to offer HIV testing refuted con-
cerns that stigma or increased work load were barriers
to routine PITC and provided further evidence for routi-
nely offering testing. Introduction of PITC during rapid
scale-up of HIV care and treatment services in Rwanda
resulted in people being diagnosed and treated for HIV
who otherwise would likely have had delayed diagnoses
or died of undiagnosed HIV disease [28,29]. Rwanda
provides a model for integrating TB-HIV services that
has resulted in the majority of patients with TB knowing
their HIV status and a dramatic scale-up of lifesaving
HIV care and treatment that coincided with a decline in
the risk of death among patients with TB/HIV.
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